---
title: "12 Health Care Stocks Moving In Monday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292487912.md"
description: "In Monday's pre-market session, healthcare stocks showed significant volatility. Pulsenmore (PLSM) surged 171.2% to $10.47, while Q32 Bio (QTTB) rose 65.92% to $18.6. Other gainers included Agenus and Basel Medical Group. Conversely, BNB Plus (BNBX) plummeted 51.3% to $0.18, with ENvue Medical and Scienture Holdings also declining sharply."
datetime: "2026-07-13T12:05:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292487912.md)
  - [en](https://longbridge.com/en/news/292487912.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292487912.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Monday's Pre-Market Session

### Gainers

-   **Pulsenmore** (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million.
-   **Q32 Bio** (NASDAQ:QTTB) stock rose 65.92% to $18.6. The market value of their outstanding shares is at $190.0 million.
-   **Agenus** (NASDAQ:AGEN) shares rose 41.49% to $4.74. The company's market cap stands at $139.5 million.
-   **Basel Medical Group** (NASDAQ:BMGL) shares increased by 10.52% to $7.3. The company's market cap stands at $10.3 million.
-   **Eikon Therapeutics** (NASDAQ:EIKN) stock moved upwards by 9.54% to $11.59. The market value of their outstanding shares is at $572.7 million.
-   **Accuray** (NASDAQ:ARAY) stock increased by 9.44% to $0.26. The market value of their outstanding shares is at $28.7 million.

### Losers

-   **BNB Plus** (NASDAQ:BNBX) stock decreased by 51.3% to $0.18 during Monday's pre-market session. The company's market cap stands at $2.7 million.
-   **ENvue Medical** (NASDAQ:FEED) stock declined by 12.66% to $0.46. The market value of their outstanding shares is at $3.2 million.
-   **Scienture Holdings** (NASDAQ:SCNX) stock decreased by 12.19% to $0.33. The market value of their outstanding shares is at $15.0 million.
-   **Bluejay Diagnostics** (NASDAQ:BJDX) stock declined by 11.02% to $1.29. The company's market cap stands at $1.5 million.
-   **Innovative Eyewear** (NASDAQ:LUCY) shares declined by 10.85% to $0.96. The market value of their outstanding shares is at $9.2 million.
-   **Nexalin Technology** (NASDAQ:NXL) stock decreased by 8.82% to $0.42. The market value of their outstanding shares is at $9.9 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [PLSM.US](https://longbridge.com/en/quote/PLSM.US.md)
- [FEED.US](https://longbridge.com/en/quote/FEED.US.md)
- [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md)
- [SCNX.US](https://longbridge.com/en/quote/SCNX.US.md)
- [BNBX.US](https://longbridge.com/en/quote/BNBX.US.md)
- [QTTB.US](https://longbridge.com/en/quote/QTTB.US.md)
- [BMGL.US](https://longbridge.com/en/quote/BMGL.US.md)
- [EIKN.US](https://longbridge.com/en/quote/EIKN.US.md)
- [ARAY.US](https://longbridge.com/en/quote/ARAY.US.md)
- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)
- [LUCY.US](https://longbridge.com/en/quote/LUCY.US.md)
- [NXL.US](https://longbridge.com/en/quote/NXL.US.md)
- [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md)
- [LUCYW.US](https://longbridge.com/en/quote/LUCYW.US.md)
- [NXLIW.US](https://longbridge.com/en/quote/NXLIW.US.md)

## Related News & Research

- [Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer](https://longbridge.com/en/news/297338792.md)
- [Agenus reports no recurrences in Phase 2 NEST trial of botensilimab plus balstilimab in resectable colon cancer](https://longbridge.com/en/news/297058971.md)
- [Insider Selling: Gloo (NASDAQ:GLOO) Major Shareholder Sells 4,000 Shares](https://longbridge.com/en/news/297377530.md)
- [IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA Stock News](https://longbridge.com/en/news/297303798.md)
- [Agenus posts investor deck spotlighting botensilimab-balstilimab neoadjuvant program in MSS colon cancer](https://longbridge.com/en/news/296536017.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**